Vistagen Therapeutics Inc (NAS:VTGN)

Q3 2026 Vistagen Therapeutics Inc Earnings Call Transcript

Feb 12, 2026 / 10:00 PM GMT

Release Date Price: $0.545 (-4.80%)

Transcript 10-Q8-K

Key Points

Positve

Vistagen Therapeutics Inc (VTGN) completed the randomized portion of the Palisade 3 phase 3 trial in social anxiety disorder, marking significant progress in their clinical stage neuroscience program.
The company is implementing innovative approaches, including artificial intelligence and machine learning, to analyze data from their studies, potentially enhancing their statistical models and regulatory strategy.
Vistagen Therapeutics Inc (VTGN) is advancing their women's health program with the planned submission of an investigational new drug application for Raficione, targeting vasomotor symptoms due to menopause.
The company has $61.8 million in cash equivalents and marketable securities, providing a solid financial position to support ongoing and future projects.
Vistagen Therapeutics Inc (VTGN) is focused on addressing significant unmet needs in social anxiety disorder and women's health, guiding their long-term strategic efforts.

Negative

The Palisade 3 trial experienced a higher placebo response, necessitating refinements and retraining to mitigate this issue in the ongoing Palisade 4 trial.
The company acknowledges the inherent risks and uncertainties in forward-looking statements, which could lead to material differences in actual results.
Vistagen Therapeutics Inc (VTGN) faces potential regulatory challenges, as any changes to their statistical analysis plan (SAP) would require resubmission and alignment with the FDA.
The open label extension studies, while providing valuable insights, are inherently uncontrolled and exploratory, which may limit the robustness of the data.
The company's reliance on AI and machine learning for data analysis introduces uncertainty, as the identification of covariants and their impact on study outcomes is not guaranteed.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VTGN.OQ - VistaGen Therapeutics Inc
Q3 2026 Vistagen Therapeutics Inc Earnings Call
Feb 12, 2026 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, everyone.

Thank you for standing by. Welcome to the Visogen Therapeutic Fiscal Year 2026, 3rd quarter corporate update, conference call and webcast. Please note that today's call is being recorded. At this time, I'd like to turn the call over to your host, Mark Mick Parkman, senior Vice President, Investor relations at Vistogen.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Mark, Thank you, Lisa, and good afternoon, everyone, and welcome to our conference call and webcast.

Earlier this afternoon, we filed our quarterly report on Form 10-Q

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.